Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program
نویسندگان
چکیده
منابع مشابه
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.
Rapamycin demonstrated broad-spectrum tumor growth inhibition activity against the in vivo panels of childhood tumors used in the Pediatric Preclinical Testing Program (PPTP). Here we have evaluated rapamycin combined with agents used frequently in the treatment of childhood malignancies. Rapamycin was tested in vitro against 23 cell lines alone or in combination with melphalan, cisplatin, vinc...
متن کاملPediatric Preclinical Testing Program (PPTP) – May 2012
In vitro testing: In vitro testing was performed using DIMSCAN, a semiautomatic fluorescencebased digital image microscopy system that quantifies viable (using fluorescein diacetate [FDA]) cell numbers in tissue culture multiwell plates [1]. Cells were incubated in the presence of drug for 96 hours. Mean fluorescence values were determined for each concentration tested and then normalized to th...
متن کاملA Review of Targeted Therapies Evaluated by the Pediatric Preclinical Testing Program for Osteosarcoma
Osteosarcoma, the most common malignant bone tumor of childhood, is a high-grade primary bone sarcoma that occurs mostly in adolescence. Standard treatment consists of surgery in combination with multi-agent chemotherapy regimens. The development and approval of imatinib for Philadelphia chromosome-positive acute lymphoblastic leukemia in children and the fully human monoclonal antibody, anti-G...
متن کاملPreclinical Development The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
The majority of gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT, an HSP90 client protein. Further secondary resistance mutations within KIT limit clinical responses to tyrosine kinase inhibitors, such as imatinib. The dependence of KIT and its mutated forms on HSP90 suggests that HSP90 inhibitionmight be a valuable treatment option for GIST,whichwould be ...
متن کاملStage Life Testing with Missing Stage Information - an EM-Algorithm Approach
We consider a stage life testing model and assume that the information at which levels the failures occurred is not available. In order to find estimates for the lifetime distribution parameters, we propose an EM-algorithm approach which interprets the lack of knowledge about the stages as missing information. Furthermore, we illustrate the implementation difficulties caused by an increasing nu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Blood & Cancer
سال: 2011
ISSN: 1545-5009
DOI: 10.1002/pbc.23154